Podophyllotoxin (International)
Scheme
BAN
ATC (Anatomical Therapeutic Chemical Classification)
D06BB04
CAS registry number (Chemical Abstracts Service)
0000518-28-5
Chemical Formula
C22-H22-O8
Molecular Weight
414
Therapeutic Categories
Dermatological agent
Topical antimitotic agent
Topical cytostatic agent
Chemical Name
Furo[3',4':6,7]naphto[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimetoxyphenyl)-, [5R-(5α,5aβ,8aα,9α)]-
Foreign Names
- Podophyllotoxinum (Latin)
- Podophyllotoxin (German)
- Podophyllotoxine (French)
Generic Names
- Podofilox (OS: USAN)
- Podophyllotoxin (OS: BAN)
- Podophyllotoxine (OS: DCF)
- Podophyllotoxin (PH: Ph. Helv. 11)
Brand Names
- Condilom
Bussié, Colombia; Bussié, Honduras - Condiver
Lacico, Colombia - Condylin
Takeda Austria, Bulgaria - Condyline
2care4, Norway; Astellas, Italy; Astellas, Kuwait; BModesto, Netherlands; Famar, Georgia; Galderma, Norway; Galderma Nordic, Denmark; Galderma Nordic, Sweden; Galderma Nordic AB, Finland; Galderma Nordic AB, Iceland; LEO Pharma, Netherlands; LEO Pharma, New Zealand; LEO Pharma, Poland; LEO Pharma, Romania; Medcor Pharmaceuticals, Netherlands; Orifarm, Norway; Sanofi-Aventis, Canada; Takeda, Australia; Takeda, Ireland; Takeda Pharma, Switzerland; Takeda UK, United Kingdom - Condyline 0.5%
LEO Pharma, France - Condyline 5 mg/ml
Takeda, Hungary - Condylox
Allergan, United States; Dr. August Wolff, Germany; Takeda, Israel; Tianjin Takeda Pharmaceutical, China - Condylox 0.5%
Takeda Pharma, Austria - Podofilm
Assos, Turkey; Paladin, Canada; Pharmascience, Hong Kong - Podofilox
Paddock Laboratories, United States - Podox 0.5%
Bussié, Colombia; Bussié, Dominican Republic; Bussié, Guatemala; Bussié, Honduras - Podoxin
Cassara, Argentina; Promofarma, Uruguay - Posalfilin [+ Salicylic acid]
Norgine, New Zealand - Wartec
BModesto, Netherlands; Dr. Fisher Farma, Netherlands; Euro Registratie, Netherlands; GlaxoSmithKline, Denmark; GlaxoSmithKline, Finland; GlaxoSmithKline, Lithuania; GlaxoSmithKline, Latvia; GlaxoSmithKline, Sweden; GlaxoSmithKline A.B.E.E., Greece; GlaxoSmithKline Australia, Australia; GSK, Czech Republic; Medcor Pharmaceuticals, Netherlands; Phoenix Labs, Netherlands; Stiefel, Brazil; Stiefel, China; Stiefel, Estonia; Stiefel, Spain; Stiefel, Hong Kong; Stiefel, Italy; Stiefel, Lebanon; Stiefel, Mexico; Stiefel, Oman; Stiefel, Romania; Stiefel, Slovakia; Stiefel, Taiwan; Stiefel, South Africa; Stiefel Laboratories Polska Sp. z.o.o., Poland - Wartec 0.15%
GlaxoSmithKline, Germany; GlaxoSmithKline, Finland; GlaxoSmithKline A.B.E.E., Greece; Stiefel, Germany - Wartec 0.5%
GlaxoSmithKline A.B.E.E., Greece - Warticon
Stiefel, United Kingdom; Stiefel, Ireland - Warticon 0.5%
GlaxoSmithKline, Cyprus - You Tuo Xin
Huawei Pharmaceutical, China
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| USAN | United States Adopted Name |
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.